soul trial oral semaglutide cardiovascular outcomes results 2024 and in Patients with Type 2 Diabetes soul trial oral semaglutide cardiovascular

Both Problems Addressed

The addition of GIP agonism in tirzepatide enhances first- and second-phase insulin secretion, reduces fasting and postprandial glucagon concentrations and therefore reduces postprandial glucose levels further

Semaglutide is a GLP-1 receptor agonist, while tirzepatide acts on both GIP and GLP-1 pathways, which is part of why both have become such important tools in modern obesity medicine (FDA Wegovy label

Please click here for Prescribing Information and Medication Guide for Ozempic pill

FDA and Novo Nordisk are testing the seized products and do not yet have information about the identity, quality or safety of these drugs